Benton J Mcgivern, MD | |
1500 Sw 10th Ave, Topeka, KS 66604-1301 | |
(785) 354-5242 | |
Not Available |
Full Name | Benton J Mcgivern |
---|---|
Gender | Male |
Speciality | Hospitalist |
Experience | 6 Years |
Location | 1500 Sw 10th Ave, Topeka, Kansas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659877470 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 04-44963 (Kansas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Stormont Vail Hospital | Topeka, KS | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Cotton O'neil Clinic Revocable Trust | 5496659195 | 576 |
News Archive
Otsuka Pharmaceutical Development & Commercialization, Inc., announced an agreement with research experts from the Columbia University Irving Center Vagelos College of Physicians and Surgeons and Mailman School of Public Health to help support the epidemiological needs of Otsuka Global Pharmacovigilance (GPV) for products, enhanced training, and employee education.
Sumitomo Heavy Industries, Ltd. announced today that it had received US FDA 510(k) clearance of its Proton Therapy System. It is the first 510(k) cleared medical device for Sumitomo. Proton therapy is a form of radiation therapy, which employs proton beams to kill cancer cells with better dose distribution in comparison with conventional x-rays. Currently 12 facilities are operational and several more are under construction in the United States, and the U.S. proton therapy market is expected to expand in the future.
Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.
GlycoVaxyn AG, a leader in the development of innovative vaccines, announced today that the Phase I study of its Shigella dysenteriae bioconjugate vaccine has been completed and met the primary and secondary endpoints: demonstration of safety and immunogenicity.
Seriously injured patients cared for at hospitals serving larger numbers of minorities are significantly more likely to die than those treated at hospitals serving mostly whites — regardless of the race of the patient, new Johns Hopkins research suggests.
› Verified 2 days ago
Entity Name | Cotton O'neil Clinic Revocable Trust |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1811944457 PECOS PAC ID: 5496659195 Enrollment ID: O20031124000674 |
News Archive
Otsuka Pharmaceutical Development & Commercialization, Inc., announced an agreement with research experts from the Columbia University Irving Center Vagelos College of Physicians and Surgeons and Mailman School of Public Health to help support the epidemiological needs of Otsuka Global Pharmacovigilance (GPV) for products, enhanced training, and employee education.
Sumitomo Heavy Industries, Ltd. announced today that it had received US FDA 510(k) clearance of its Proton Therapy System. It is the first 510(k) cleared medical device for Sumitomo. Proton therapy is a form of radiation therapy, which employs proton beams to kill cancer cells with better dose distribution in comparison with conventional x-rays. Currently 12 facilities are operational and several more are under construction in the United States, and the U.S. proton therapy market is expected to expand in the future.
Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.
GlycoVaxyn AG, a leader in the development of innovative vaccines, announced today that the Phase I study of its Shigella dysenteriae bioconjugate vaccine has been completed and met the primary and secondary endpoints: demonstration of safety and immunogenicity.
Seriously injured patients cared for at hospitals serving larger numbers of minorities are significantly more likely to die than those treated at hospitals serving mostly whites — regardless of the race of the patient, new Johns Hopkins research suggests.
› Verified 2 days ago
Entity Name | Stormont Vail Health Flint Hills Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1952018608 PECOS PAC ID: 9032587472 Enrollment ID: O20230429000051 |
News Archive
Otsuka Pharmaceutical Development & Commercialization, Inc., announced an agreement with research experts from the Columbia University Irving Center Vagelos College of Physicians and Surgeons and Mailman School of Public Health to help support the epidemiological needs of Otsuka Global Pharmacovigilance (GPV) for products, enhanced training, and employee education.
Sumitomo Heavy Industries, Ltd. announced today that it had received US FDA 510(k) clearance of its Proton Therapy System. It is the first 510(k) cleared medical device for Sumitomo. Proton therapy is a form of radiation therapy, which employs proton beams to kill cancer cells with better dose distribution in comparison with conventional x-rays. Currently 12 facilities are operational and several more are under construction in the United States, and the U.S. proton therapy market is expected to expand in the future.
Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.
GlycoVaxyn AG, a leader in the development of innovative vaccines, announced today that the Phase I study of its Shigella dysenteriae bioconjugate vaccine has been completed and met the primary and secondary endpoints: demonstration of safety and immunogenicity.
Seriously injured patients cared for at hospitals serving larger numbers of minorities are significantly more likely to die than those treated at hospitals serving mostly whites — regardless of the race of the patient, new Johns Hopkins research suggests.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Benton J Mcgivern, MD 1500 Sw 10th Ave, Topeka, KS 66604-1301 Ph: (785) 354-5242 | Benton J Mcgivern, MD 1500 Sw 10th Ave, Topeka, KS 66604-1301 Ph: (785) 354-5242 |
News Archive
Otsuka Pharmaceutical Development & Commercialization, Inc., announced an agreement with research experts from the Columbia University Irving Center Vagelos College of Physicians and Surgeons and Mailman School of Public Health to help support the epidemiological needs of Otsuka Global Pharmacovigilance (GPV) for products, enhanced training, and employee education.
Sumitomo Heavy Industries, Ltd. announced today that it had received US FDA 510(k) clearance of its Proton Therapy System. It is the first 510(k) cleared medical device for Sumitomo. Proton therapy is a form of radiation therapy, which employs proton beams to kill cancer cells with better dose distribution in comparison with conventional x-rays. Currently 12 facilities are operational and several more are under construction in the United States, and the U.S. proton therapy market is expected to expand in the future.
Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.
GlycoVaxyn AG, a leader in the development of innovative vaccines, announced today that the Phase I study of its Shigella dysenteriae bioconjugate vaccine has been completed and met the primary and secondary endpoints: demonstration of safety and immunogenicity.
Seriously injured patients cared for at hospitals serving larger numbers of minorities are significantly more likely to die than those treated at hospitals serving mostly whites — regardless of the race of the patient, new Johns Hopkins research suggests.
› Verified 2 days ago
Dr. Amer Alshekh Mousa, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 Sw 10th Ave, Topeka, KS 66604 Phone: 785-354-5242 | |
Jeffery Parker Rhoads, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 7821 Sw 12th St, Topeka, KS 66615 Phone: 785-408-5824 | |
Achuta Uppu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 Sw 10th Ave, Topeka, KS 66604 Phone: 785-354-6000 | |
Dr. Keith E Kentch, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 Sw 10th Ave, Topeka, KS 66604 Phone: 785-354-5242 | |
Ashraf Alhafez, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 Sw 10th Ave, Stormont-vail Health Care, Topeka, KS 66604 Phone: 785-354-5242 | |
Corbin J Mcilvain, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 Sw 10th Ave, Topeka, KS 66604 Phone: 785-354-5242 | |
Dr. Hossam Saher Ahmad Abed, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1500 Sw 10th Ave, Topeka, KS 66604 Phone: 785-354-5242 |